Outcomes Using TORS or Definitive Chemoradiation for T3/T4 HPV+ Oropharynx Cancer

E J Anstadt,R M Carey,D Shimunov,A Lin, A R Barsky,C M Wright, A Doucette, S D Swisher-McClure, R Cohen,J Bauml, G S Weinstein, B O'Malley, A Chalian,C Rassekh,K Rajasekaran, D Basu, S B Cannady, R Brody,J Newman,J N Lukens

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS（2021）

引用 0|浏览4

暂无评分

摘要

This large, single-institution series of patients with T3/T4 HPV+ OPSCC treated with either dCRT or upfront TORS +/- adjuvant therapy shows high FF-LRF and low rates of LRF leading to death regardless of treatment. Even in patients with advanced T stage, dCRT was able to obtain excellent disease outcomes. Future prospective studies are warranted to determine which combinations of multimodality therapy are optimal for LA HPV+ OPSCC, incorporating both oncologic and functional outcome endpoints.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要